Welcome to the international HTA database

Showing [23371 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2013	Health Quality Ontario (HQO)	OHTAC recommendation: midurethral slings for women with stress urinary incontinence
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Ellex 2RT™ for early age-related macular degeneration
2013	University of York	Advance care planning
2013	Basque Office for Health Technology Assessment (OSTEBA)	[A study of the use of clinical practice guidelines in specialized care: barriers and facilitators to implementation]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-03 (sitagliptin/metformin)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Implantation of a lumbar artificial endoprosthesis (anuloplasty/anular repair device)]
2013	Agency for Healthcare Research and Quality (AHRQ)	Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer
2013	NIHR Horizon Scanning Centre (NIHR HSC)	OssDsign™ Cranio PSI for skull repair
2013	University of York	Primary care 'in-reach' in hospital settings
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Design of an interaction protocol between Primary Care and Hospitals to improve early detection and monitoring of patients with multiple sclerosis]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-16 (vildagliptin)]
2013	The Netherlands Organisation for Health Research and Development (ZonMw)	[Neurodevelopmental outcome after neonatal hypoglycemia: a multi-center randomized controlled trial comparing intensive treatment versus expectant glucose monitoring in 'high risk' newborns]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Repair of cartilage defects via matrix-associated autologous chondrocyte immigration]
2013	Agency for Healthcare Research and Quality (AHRQ)	Screening for cognitive impairment in older adults: an evidence update for the U.S. Preventive Services Task Force.
2013	NIHR Horizon Scanning Centre (NIHR HSC)	SmartSensor electronic oral glucose tolerance test for screening for diabetes
2013	Medical Services Advisory Committee (MSAC)	Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Terminal care: systematic review of organisational models in palliative care and survey of health professionals regarding the situation of palliative care in a region of the Basque Country]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-17 (vildagliptin/metformin)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB)]
2013	Agency for Healthcare Research and Quality (AHRQ)	Screening for lung cancer: systematic review to update the U.S. Preventive Services Task Force Recommendation
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Smart-Glasses depth-based visual aids for the partially sighted
2013	Medical Services Advisory Committee (MSAC)	Cell enrichment liquid based cytology (LBC) in routine screening for the prevention of cervical cancer
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Results of the perinatal care of very premature children in the health system of the Basque Country]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Endovascular repair of aortic aneurysms]
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Full Sense™ device for obesity
2013	Medical Services Advisory Committee (MSAC)	Transcatheter closure of patent ductus arteriosus
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the status, systematic review and validation of a diagnostic algorithm for pulmonary thromboembolism (PTE) in the hospital emergency services of the Basque Health Service]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Percutaneous transcatheter closure of prosthetic mitral and aortic paravalvular leaks]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Screening tools to identify adults with mild cognitive impairment not associated with dementia: a review of diagnostic accuracy, effectiveness and guidelines
2013	Medical Services Advisory Committee (MSAC)	Epidermal Growth Factor Receptor (EGFR) testing to determine eligibility for afatinib treatment in patients with locally advanced or metastatic non-small-cell lung cancer.
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Models of collaboration and intervention between primary care and mental health in the care of patients diagnosed with depression: results of a meta-review]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ponatinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM)]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Mini C-arm imagers for the follow-up of orthopedic patients: clinical effectiveness
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dressings and care of skin graft sites: a review of clinical evidence and guidelines
2013	Medical Services Advisory Committee (MSAC)	Matrix-induced autologous chondrocyte implant
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Vismodegib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Percutaneous transluminal coronary angioplasty (PTCA) with paclitaxel-coated drug-eluting balloon (DEB). Update 2013]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Optimal care of chronic, non-healing, lower extremity wounds: a review of clinical evidence and guidelines
2013	Medical Services Advisory Committee (MSAC)	Sexual health medicine consultation items
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Hemoperfusion with polymyxin-B for the treatment of sepsis of abdominal origin by gram negative microorganisms]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "COPD"]
2013	Adelaide Health Technology Assessment (AHTA)	Australian guidelines for the treatment of acute stress disorder and posttraumatic stress disorder
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Duodeno-jejunal bypass liner (DJBL) for patients with obesity, with/without type 2 diabetes mellitus]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Copper intra-uterine devices as a contraceptive for adult women: a review of clinical effectiveness and safety
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Naloxone for use in long-term care and palliative care: clinical effectiveness, safety, and guidelines
2013	Medical Services Advisory Committee (MSAC)	Addiction medicine consultation items
2013	Basque Office for Health Technology Assessment (OSTEBA)	[CORREX® aortic valve bypass for treatment of severe aortic stenosis]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pomalidomide - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment))]
2013	The Netherlands Organisation for Health Research and Development (ZonMw)	[Pharmacogenetic testing in the clinical setting: is screening for TPMT genotype a cost-effective treatment strategy? The first prospective randomized controlled trial within the Dutch health care system]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[P16/Ki-67 dual stain in the triage of PAPIII/IIID cytology in cervical cancer screening]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Side rails on beds in long-term and residential care facilities: safety and evidence based guidelines
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interventions for the prevention or management of childhood obesity: a review of the clinical evidence
2013	Medical Services Advisory Committee (MSAC)	Genetic testing for hereditary mutations in the RET gene
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "asthma"]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Pomalidomide (Pomalyst®) for the treatment of refractory multiple myeloma or relapsed and refractory multiple myeloma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Photo-activated disinfection therapy for dental surgery: review of the clinical effectiveness
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transobturator slings for urinary incontinence: clinical effectiveness and guidelines
2013	Medical Services Advisory Committee (MSAC)	Implantation of fiducial markers into the prostate gland or prostate surgical bed for external beam radiotherapy
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Saxagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Regorafenib (Stivarga®) in pts with metastatic colorectal cancer (CRC) who have progressed after standard therapy
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Antipsychotics for the management of agitation in adults with personality disorders or cognitive impairment: a review of the clinical effectiveness and guidelines
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Removal of physical restraints in long term care settings: clinical safety and harm
2013	Medical Services Advisory Committee (MSAC)	Gene expression profiling of 21 genes in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Mental health rehabilitation for children and adolescents – a literature overview of indications, outcomes and evaluation instruments]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Heating standards for clinical interventions: clinical evidence
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Computed tomography angiography versus computed tomography for the diagnosis and management of hyperacute stroke: a review of comparative clinical evidence and guidelines
2013	Medical Services Advisory Committee (MSAC)	Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Zostavax for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA core model for rapid relative effectiveness assessment. Pilot-ID: WP-SA-1]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transcendental meditation for posttraumatic stress disorder, depression, and anxiety: a review of clinical effectiveness
2013	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Intraoperative radiation therapy in the treatment of breast cancer]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bioabsorbable stents for adults with coronary artery disease: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2013	Medical Services Advisory Committee (MSAC)	Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent)
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Regorafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Identifying ineffective interventions and health technologies: models and their implementation]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	GreenLight laser for the treatment of benign prostatic hypertrophy: a review of clinical and cost-effectiveness, and safety
2013	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Efficacy and safety of percutaneous and transapical aortic valve implantation in the treatment of severe aortic stenosis. Systematic review]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Diabetes screening for asymptomatic adults: a review of the diagnostic accuracy, cost effectiveness, and guidelines
2013	Medical Services Advisory Committee (MSAC)	Insertion, replacement, or removal of a cardiac resynchronisation therapy device capable of defibrillation (CRT-D) for mild, moderate or severe chronic heart failure (NYHA II, III or IV)
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aflibercept (Eylea) extension of approval - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Management of congestive heart failure in primary and community care: guidelines
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety
2013	Medical Services Advisory Committee (MSAC)	Single balloon enteroscopy
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Teriflunomide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Occupational therapy in children; Part 1 – Literature review on indications, utilisation and recommendations]
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Procedures and tools for patients at risk for creutzfeldt-jakob disease: guidelines and identification
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nutritional supplementation for patients with cancer: clinical effectiveness and guidelines
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dabrafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Medical Services Advisory Committee (MSAC)	Optical coherence tomography, for the diagnosis and monitoring of treatment effectiveness with aflibercept in patients with central retinal vein occlusion (co-dependent)
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Evidence requirements for the authorization and reimbursement of high-risk medical devices in the USA, Europe, Australia and Canada: an analysis of seven high-risk medical devices
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nd:YAG laser for the treatment of patients with hidradenitis suppurativa: a review of the clinical effectiveness, cost-effectiveness, and safety
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Non-surgical debridement for chronic lower extremity wounds: clinical effectiveness and guidelines
2013	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Linagliptin (Trajenta®) 5 mg film-coated tablets
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Afatinib (Gilotrif®) for first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)